Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

China Biologic's Shandong Taibang Subsidiary Donates Lifesaving Plasma Products for the Injured in the Ya'an Earthquake



    China Biologic's Shandong Taibang Subsidiary Donates Lifesaving Plasma
               Products for the Injured in the Ya'an Earthquake

PR Newswire

BEIJING, April 24, 2013

BEIJING, April 24, 2013 /PRNewswire-FirstCall/ -- China Biologic Products,
Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully
integrated plasma-based biopharmaceutical company in China, today announced
that it has donated 500 bottles of human albumin and 1000 bottles of Tetanus
immunoglobulin through its Shandong Taibang subsidiary for those injured in
the devastating earthquake that struck Lushan County, Ya'an City located in
China's Sichuan province on April 21, 2013. The donation will be delivered
immediately through the Shandong Provincial Health Bureau to the ravaged area.

Mr. David (Xiaoying) Gao, Chairman & Chief Executive Officer of China
Biologic, commented, "As a leading plasma-based biopharmaceutical company in
China, it is part of our corporate social responsibility policy to help
Chinese citizens, particularly during times of extreme need. We extend our
condolences and thoughts to any families who have suffered through this
tragedy and wish for a prompt recovery for the people in this quake-hit
region."

About China Biologic Products, Inc.

China Biologic Products, Inc. (Nasdaq: CBPO), is a leading fully integrated
plasma-based biopharmaceutical company in China. The Company's products are
used as critical therapies during medical emergencies and for the prevention
and treatment of life-threatening diseases and immune-deficiency related
diseases. China Biologic is headquartered in Beijing and manufactures over 20
plasma-based products through its indirect majority-owned subsidiaries,
Shandong Taibang Biological Products Co., Ltd. and Guiyang Dalin Biologic
Technologies Co., Ltd. The Company also has an equity investment in Xi'an
Huitian Blood Products Co., Ltd. The Company sells its products to hospitals
and other healthcare facilities in China. For additional information, please
see the Company's website www.chinabiologic.com.

Safe Harbor Statement

This news release may contain certain "forward-looking statements" relating to
the business of China Biologic Products, Inc. and its subsidiaries. All
statements, other than statements of historical fact included herein, are
"forward-looking statements." These forward-looking statements are often
identified by the use of forward-looking terminology such as "believes,"
"expects," or similar expressions, and involve known and unknown risks and
uncertainties. Although the Company believes that the expectations reflected
in these forward-looking statements are reasonable, they involve assumptions,
risks, and uncertainties, and these expectations may prove to be incorrect.

Investors should not place undue reliance on these forward-looking statements,
which speak only as of the date of this news release. The Company's actual
results could differ materially from those anticipated in these
forward-looking statements as a result of a variety of factors, including its
potential inability to achieve the expected operating and financial
performance in 2012, potential inability to find alternative sources of
plasma, potential inability to increase production at permitted sites,
potential inability to mitigate the financial consequences of a temporarily
reduced raw plasma supply through cost cutting or other efficiencies, and
potential additional regulatory restrictions on its operations and those
additional risks and uncertainties discussed in the Company's periodic reports
that are filed with the Securities and Exchange Commission and available on
its website (http://www.sec.gov). All forward-looking statements attributable
to the Company or persons acting on its behalf are expressly qualified in
their entirety by these factors. Other than as required under the securities
laws, the Company does not assume a duty to update these forward-looking
statements.

Contact:

China Biologic Products, Inc.
Mr. Ming Yin
Vice President
Phone: +86-10-6598-3099
Email: ir@chinabiologic.com

ICR Inc.
Mr. Bill Zima
Phone: +86-10-6583-7511 or +1-646-405-5191
E-mail: bill.zima@icrinc.com

SOURCE China Biologic Products, Inc.

Website: http://www.chinabiologic.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement